Everything below concerns tesamorelin. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-11-27. Numbers and descriptions here follow the published literature rather than marketing material.
Tesamorelin binds to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary. Receptor activation increases intracellular cyclic AMP and promotes synthesis and secretion of growth hormone. Because the peptide mimics endogenous GHRH, it amplifies the normal pulsatile release of growth hormone rather than providing exogenous growth hormone directly. This upstream action distinguishes tesamorelin from recombinant growth hormone preparations and from growth hormone secretagogues that act at different receptors.
Stimulated growth hormone release leads to hepatic production of insulin-like growth factor 1, a key mediator of many growth hormone effects. In clinical studies, tesamorelin increased IGF-1 levels in a dose-dependent manner, although the response varies among individuals. The drug's effect on visceral fat is thought to involve growth hormone-mediated lipolysis and altered adipocyte metabolism. Muscle mass and lean body mass have also been assessed as secondary outcomes, but changes are generally smaller and less consistent than fat reductions.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.
| Property | Value | Notes |
|---|---|---|
| Primary target | Growth hormone-releasing hormone receptor | Located on anterior pituitary somatotroph cells. |
| Receptor class | G protein-coupled receptor | Activation increases intracellular cyclic AMP. |
| Main downstream hormone | Growth hormone and insulin-like growth factor 1 | Growth hormone release precedes IGF-1 elevation. |
| Primary studied effect | Reduction in visceral adipose tissue | Measured by computed tomography in clinical trials. |
| Approximate half-life | 26–38 minutes after subcutaneous administration | Values vary by assay and study population. |
Binding of tesamorelin to the growth hormone-releasing hormone receptor on anterior pituitary somatotrophs activates a Gs protein pathway, raises cyclic AMP, and triggers release of stored growth hormone into the bloodstream. Because the analogue resists dipeptidyl peptidase-4, its plasma residence time exceeds that of native GHRH, producing a larger and more sustained secretory signal. The released growth hormone then acts on the liver and peripheral tissues to raise insulin-like growth factor 1, which feeds back on the hypothalamus and pituitary. This axis explains both the intended effects on fat distribution and the biological markers used to track them.
Studies of the compound rely on imaging and laboratory endpoints rather than on symptoms alone. Visceral adipose tissue is usually quantified by computed tomography or magnetic resonance imaging at the level of the abdomen, with waist circumference serving as a cheaper but less specific proxy. Blood work tracks insulin-like growth factor 1, fasting glucose, glycated hemoglobin, and lipid fractions. In the pivotal trials the imaging endpoint fell by roughly fifteen to twenty percent over six months, subcutaneous fat changed little, and the visceral fat returned toward baseline after treatment stopped, a pattern that shapes how clinicians discuss durability.
Whether the drug improves hard clinical outcomes is not settled. No completed trial has shown a reduction in heart attacks or strokes among treated patients, although a dedicated cardiovascular outcomes study has been discussed in the literature. Investigators have also examined hepatic fat in people with HIV and fatty liver disease, cognitive measures in small cohorts, and changes in bone density. Regulatory labeling emphasizes monitoring of insulin-like growth factor 1 because supraphysiologic levels raise questions about tissue growth, and the clinical significance of that signal remains an open question rather than a demonstrated harm.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
Cordyceps chanhua is an ascomycete fungus that parasitizes cicada larvae found in Southern China. It forms white and yellow asexual fruiting structures resembling synnema. It is known in Traditional Chinese Medicine as Chan Hua which means "cicada flower". Its medicinal uses date back to the fifth century AD in China. It can also be used in various foods and tonics. Chan-hua is previously misidentified as Isaria cicadae, another pathogen of cicada larvae. However, this name describes a fungus found in Brazil in 1838 with significant morphological and DNA differences. Other misattributed names include Cordyceps cicadae and Cordyceps sobolifera. Due to widespread misidentification, "Isaria cicadae" has been reported to exist on other continents.
A-DNA One of three main biologically active structural conformations of the DNA double helix, along with B-DNA and Z-DNA. The A-form helix has a right-handed twist with 11 base pairs per full turn, only slightly more compact than B-DNA, but its bases are sharply tilted with respect to the helical axis. It is often favored in dehydrated conditions and within sequences of consecutive purine nucleotides (e.g. GAAGGGGA); it is also the primary conformation adopted by double-stranded RNA and RNA-DNA hybrids.
In 1912, Knoxvillians replaced their mayor-alderman form of government with a commissioner form of government that consisted of five commissioners elected at-large, and a mayor chosen from among the five. Following the 1917 annexations, the city began to struggle as it extended services to the newly annexed areas, and it became clear the new government was ineffective at dealing with the city's financial issues. In 1923, the city voted to replace the commissioners with a city manager-council form of government, which involved the election of a city council, who would then hire a city manager to oversee the city's business affairs. The first city manager hired by Knoxville was Louis Brownlow, the successful city manager of Petersburg, Virginia, and a cousin of Parson Brownlow. When Brownlow arrived in Knoxville, he was horrified by the city's condition, later writing that he found "something new and more disturbing" every day. There were no paved roads connecting Knoxville with other major cities. The lone operable tank of the city's waterworks was full of cracks that Knoxvillians had been lazily plugging with gunny sacks. The city hospital was unable to buy drugs, as it was deeply in debt, and its credit had been cut off. City Hall, then located on Market Square, was filthy, noisy and disorganized.
In addition to drugs being specific to a certain kind of organism (bacteria, fungi, etc.), some drugs are specific to a certain genus or species of organism, and will not work on other organisms. Because of this specificity, medical microbiologists must consider the effectiveness of certain antimicrobial drugs when making recommendations. Additionally, strains of an organism may be resistant to a certain drug or class of drug, even when it is typically effective against the species. These strains, termed resistant strains, present a serious public health concern of growing importance to the medical industry as the spread of antibiotic resistance worsens. Antimicrobial resistance is an increasingly problematic issue that leads to millions of deaths every year. Adapting to the antibiotic medicine means it no longer can kill them or stop their growth. These bacterial infections can become extremely difficult to treat since the options to remove that bacterium are now slimmer. Antibiotic resistance can be caused by overuse, misuse, spontaneous resistance, and transmitted resistance. Taking antibiotics that are not prescribed to you allows naturally resistant bacteria to survive and become "superbugs." Misuse of antibiotics includes forgetting to take one or more antibiotic doses, stopping treatment too soon, or using someone else's medicine. Mutated bacteria become increasingly resistant to medicine.
Sources: en.wikipedia.org
== History and etymology == Glycine was discovered in 1820 by French chemist Henri Braconnot when he hydrolyzed gelatin by boiling it with sulfuric acid. He originally called it "sugar of gelatin", but French chemist Jean-Baptiste Boussingault showed in 1838 that it contained nitrogen. In 1847 American scientist Eben Norton Horsford, then a student of the German chemist Justus von Liebig, proposed the name "glycocoll"; however, the Swedish chemist Berzelius suggested the simpler current name a year later. The name comes from the Greek word γλυκύς "sweet tasting" (which is also related to the prefixes glyco- and gluco-, as in glycoprotein and glucose). In 1858, the French chemist Auguste Cahours determined that glycine was an amine of acetic acid.
Poppy straw (also known as opium straw, mowed opium straw, crushed poppy capsule, poppy chaff, or poppy husk) is derived from opium poppies (Papaver somniferum) that are harvested when fully mature and dried by mechanical means. Opium poppy straw is what remains after the seed pods have been harvested — that is, the dried stalks, stem and leaves of poppies grown for their seeds. The field-dried leaves, stalk, and seed pod are then used in commercial manufacture of morphine or other poppy-alkaloid derived drugs, by first processing the material, separating the seeds, and then making concentrate of poppy straw where no extraction using the traditional methods of latex extraction has been made. The straw was originally considered an agricultural by-product of the mechanised poppy seed harvest, which was primarily grown for its edible and oil-producing seed. This changed in 1927 when János Kabay developed a chemical process to extract morphine from the crushed capsule. Concentrated poppy straw, consisting mainly of the crushed capsule without the seeds, soon became a valuable source of morphine. Today, concentrate of poppy straw is a major source of many opiates and other alkaloids. It is the source of 90% of the world supply of legal morphine (for medical and scientific use) and in some countries it also is a source of illegal morphine, which could be processed into illegal heroin. The 1961 Single Convention on Narcotic Drugs defines poppy straw as "all parts (except the seeds) of the opium poppy, after mowing".
=== Soft tissue sarcoma === In 2007, the European Commission gave authorization for the marketing of trabectedin, under the trade name Yondelis, "for the treatment of patients with advanced soft tissue sarcoma, after failure of anthracyclines and ifosfamide, or who are unsuited to receive these agents". The European Medicine Agency's evaluating committee, the Committee for Medicinal Products for Human Use (CHMP), observed that trabectedin had not been evaluated in an adequately designed and analyzed randomized controlled trial against current best care, and that the clinical efficacy data were mainly based on patients with liposarcoma and leiomyosarcoma. However, the pivotal study did show a significant difference between two different trabectedin treatment regimens, and due to the rarity of the disease, the CHMP considered that marketing authorization could be granted under exceptional circumstances. As part of the approval PharmaMar agreed to conduct a further trial to identify whether any specific chromosomal translocations could be used to predict responsiveness to trabectedin. Trabectedin is also approved in South Korea and Russia. In 2015, (after a phase III study comparing trabectedin with dacarbazine), the US FDA approved trabectedin (Yondelis) for the treatment of liposarcoma and leiomyosarcoma that is either unresectable or has metastasized. Patients must have received prior chemotherapy with an anthracycline.
Sources: en.wikipedia.org
In stage 1, creatinine and SDMA values are still within the normal range. However, there are other disorders of kidney function, such as an inadequate ability to concentrate, protein loss via the urine, morphological kidney changes or an increase in the values on repeated measurements. Creatinine and SDMA values often indicate a different stage. This may be due to the biological fluctuation range, concomitant diseases, influencing factors outside the kidney and pre-analytical causes. In this case, staging should be based on the higher value and the determination should be repeated after two to four weeks.
== Structural changes == disulfide bridges, the covalent linkage of two cysteine amino acids lysine-cysteine bridges, the covalent linkage of 1 lysine and 1 or 2 cysteine residues via an oxygen atom (NOS and SONOS bridges) proteolytic cleavage, cleavage of a protein at a peptide bond isoaspartate formation, via the cyclisation of asparagine or aspartic acid amino-acid residues racemization of serine by protein-serine epimerase of alanine in dermorphin, a frog opioid peptide of methionine in deltorphin, also a frog opioid peptide protein splicing, self-catalytic removal of inteins analogous to mRNA processing
=== Environmental agents === Teratogens are environmental agents that cause birth defects. Some agents that are theorized to cause birth defects have also been suggested as potential autism risk factors, although there is little to no scientific evidence to back such claims. These include exposure of the embryo to valproic acid, thalidomide or misoprostol. These cases are rare. Questions have also been raised whether ethanol (grain alcohol) increases autism risk, as part of fetal alcohol syndrome or alcohol-related birth defects. All known teratogens appear to act during the first eight weeks from conception, and though this does not exclude the possibility that autism can be initiated or affected later, it is strong evidence that autism arises very early in development.
=== The Lorenzo era (2022–present) === On 2 June 2022, the federation appointed Néstor Lorenzo, an Argentine who had served as Pékerman's assistant, on a four-year contract. On 28 February 2023, it launched Fútbol con Futuro, a FIFA-supported development programme running from 2022 to 2025 and intended to strengthen the structures of all national teams. Under Lorenzo, Colombia assembled a 28-match unbeaten run that included a 1–0 win over Spain in London through Daniel Muñoz. At the 2024 Copa América in the United States they won their group with seven points, beating Paraguay 2–1 and Costa Rica 3–0 and drawing 1–1 with Brazil, then beat Panama 5–0 in the quarter-finals and Uruguay 1–0 in the semi-final at Charlotte. In the final at Miami Gardens on 14 July, Argentina won 1–0 through a Lautaro Martínez goal in the 112th minute, ending the unbeaten run. Kick-off at the Hard Rock Stadium was delayed by roughly 80 minutes after unticketed supporters breached the perimeter gates; Miami-Dade County officials later attributed the disorder to inadequate intelligence gathering and insufficient security perimeters, and organisers settled a resulting class action for $14 million in November 2025. Colombia qualified for the 2026 FIFA World Cup on 4 September 2025 with a 3–0 win over Bolivia in Barranquilla, securing a seventh World Cup appearance and ending a six-match run without a victory.
Sources: en.wikipedia.org
It targets the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Binding stimulates cyclic AMP signaling and growth hormone secretion. This is the same receptor used by endogenous GHRH.
It does not act directly on adipose tissue as a primary mechanism. Instead, it increases endogenous growth hormone, which then influences lipolysis and fat distribution. The reduction in visceral fat is an indirect pharmacodynamic effect.
Tesamorelin acts upstream at the pituitary to amplify natural pulsatile growth hormone release. Growth hormone injections provide exogenous hormone and bypass pituitary regulation. The two approaches therefore differ in feedback control and hormonal dynamics.
The principal difference is a chemical cap on the N-terminal tyrosine that prevents rapid enzymatic cleavage. Native GHRH is degraded within minutes in plasma, whereas the modified peptide persists considerably longer. The amino acid backbone otherwise mirrors the natural hormone.